Computer-aided drug design has revolutionized the landscape of drug discovery, accompanied by a new era of innovation and efficiency of novel therapeutic agents. This article review explores the diverse innovations and practical applications that have propelled CADD into the forefront of modern medicine. CADD, a multidisciplinary field at the interaction of biology, chemistry, and computational science, offers a toolkit for the identification and development of pharmaceutical compounds. It has the ability to predict molecular interaction between drug and biological targets with remarkable precision, reducing the dependency on laborious and costly laboratory experiments. The review deals with two primary domains of CADD: structure-based and ligand-based design. This three-dimensional protein structure and screening of chemical libraries have led to rational changes. The analysis of known drug compounds' chemical and biological properties has enabled the creation of predictive models, opening new routes for drug discovery. The impact of CADD on the pharmaceutical industry is clear. This review highlights its instrumental role in the development of antiviral agents, cancer therapeutics, and treatment for various diseases. The transformation potential of CADD is not without challenges, including the need for substantial computational resources and the essential requirement of experimental analysis. The synergy between innovation and practical application is clear, driving unexpected efficiency and precision in the identification of therapeutic solutions. As pharmaceutical research continues to evolve, the role of CADD remains pivotal, assuring the rapid translation of scientific innovation into real-world medical advancements.
One of the most popular sectors in the tech and healthcare industries right now is artificial intelligence. In the search and development of new drugs, artificial intelligence is essential. Drug design using computer-assisted design (CADD) has supplanted the traditional approach. Artificial intelligence is assisting businesses in the development of new drugs in a faster, more affordable, and more efficient manner, saving money and manpower in the process of creating new drug molecules to treat any disease. Quantitative structure-activity relationship (QSAR) analysis, activity scoring, in silico testing, biomarker development, and mode of action identification are all aided by artificial intelligence. It is revolutionizing these sectors by swiftly identifying potential drug candidates, efficiently conducting clinical trials, and customizing patient care. AI optimizes drug manufacturing processes, augments safety monitoring, and streamlines market analysis. In clinical trials, AI streamlines patient recruitment and ensures more precise trial designs, leading to faster and more efficient research. AI empowers personalized medicine by tailoring treatment plans and drug dosages to individual patient characteristics. AI also optimizes pharmaceutical manufacturing processes, amplifies safety monitoring by analyzing real-time data for adverse events, and supports market analysis and sales strategies. AI in the pharmaceutical industry is a multifaceted tool. Artificial Intelligence (AI) has the potential to streamline complex pharmaceutical regulatory matters. Regulatory processes like audits and dossier completion can be automated with AI tools.
: Chronic wounds generally take a lot of time to recover, which becomes a cause of worry for the patient and also makes it difficult to manage them. Chronic wound affects the minds of millions of people worldwide, which results in a high mortality rate. Nanomedicine has emerged as a promising tool in addressing this issue of chronic wounds. Nanomedicine in chronic wound healing holds the potential to revolutionize wound care by offering various personalized treatments and improving patient outcomes. Advanced wound dressings and nanofibresscaffolds promote tissue regeneration, which also accelerates wound closure. Nanomedicine is also able to provoke the various cellular and molecular mechanisms that are involved in the wound microenvironment, showing the anti-inflammatory, antibacterial, and angiogenetic effects. The gene therapy and various inflammation modulations using this emerging tool of nanotechnology show promising results in managing the various chronic wounds. Nanomedicine offers innovative approaches to address these challenges. Nanomedicine also plays a crucial role in tissue engineering, which can also be used for chronic wound treatment. Nanotechnology has enabled the various development of advanced wound dressings and has improved various properties. Nanomedicine also uses antimicrobial nanomaterials, such as silver nanoparticles, to combat the various infections in chronic wounds. The main aim of the review is to provide a concise overview of nanomedicine as a recent tool in healing chronic wounds and also its various opportunities for curing chronic wounds.
22 July 2026 in Applied Drug Research, Clinical Trials and Regulatory Affairs
Substances added to a medication that are not the active component or ingredients are known as excipients. These are included in a product to aid in its formulation, stability, bioavailability, and patient acceptability. Excipients are regulated by evaluating their safety and effectiveness as well as their effect on the drug product's quality, stability, and bioavailability. For example, the Inactive Ingredient Database, a list of approved excipients issued by the Food and Drug Authority contains details about each excipient's composition, purpose, and safety. In order to guarantee that the excipient is consistently of the required quality and is not contaminated, the Food and Drug Authority additionally mandates that excipients be produced in compliance with the most recent Good Manufacturing Practices requirements. The possibility of toxicity, mutagenicity, and adverse consequences is assessed for excipients. To guarantee the secure application of excipients, the European Medicines Agency also mandates that they be prepared in compliance with Continuous Good Manufacturing Practice criteria and labelled appropriately. Regulatory bodies contribute to the security and efficiency of pharmaceutical products for patients by establishing criteria and recommendations for the production and use of excipients. This study reviews the safety and efficacy of processed excipients, their impact on the quality, stability, and bioavailability of pharmaceutical products, and the policies and procedures used by regulatory agencies to ensure these aspects. The Food and Drug Authority Inactive Ingredient Database, Good Manufacturing Practices rules, and the European Medicines Agency safety and compatibility evaluations are discussed. In order to guarantee patient safety and efficacy, regulatory bodies play a critical role in making sure that the excipients used in pharmaceutical products are of the highest calibre, safe, and efficient.
1 February 2026 in Progress in Nanoscience and Nanotechnology
Electrospinning has been identified as a promising and effective method for the fabrication of nanofibers with controlled morphology, high surface area, and tunable porosity. Such characteristics make electrospun nanofibers of high interest in biomedical engineering, drug delivery, filtration, energy storage, and tissue engineering. This review presents a systematic summary of electrospinning- based nanofiber formulation, including the effect of polymer choice, solvent systems, and process conditions like voltage, flow rate, and collector type on fiber properties. Moreover, recent advances in modified electrospinning methods, such as coaxial, emulsion, and melt electrospinning, are discussed to emphasize their potential in the fabrication of functionalized nanofibers. Large-scale production issues, reproducibility, and fibre uniformity issues are also discussed, along with emerging trends for overcoming such issues. Through the summary of key trends and innovations, this review seeks to present valuable insights into the status and future direction of electrospun nanofiber formulation.
A significant clinical care challenge is infection management in wounds, particularly in light of the growing incidence of bacteria resistant to antibiotics. Innovative wound-healing materials have prompted the incorporation of cutting-edge technology, such hydrogels coated with silver nanoparticles (AgNPs), which provide dual-action antibacterial tactics. The broad-spectrum antibacterial qualities of silver nanoparticles cause structural damage and growth inhibition by interacting with bacterial cell membranes and releasing silver ions. By targeting the development of bacterial cell walls, cell wall synthesis inhibitors further reduce bacterial growth and improve the overall effectiveness of treatment. Additional advantages of incorporating these agents into the hydrogel matrix include moisture retention, controlled medication release, and the capacity to adapt to wound surfaces, all of which support the development of a favourable environment for tissue regeneration. Additionally, the hydrogels may release antibiotics and silver nanoparticles locally and continuously, promoting wound healing and avoiding infections. The mechanisms of cell wall synthesis inhibitors and silver nanoparticles in wound infection prevention are examined in this study, emphasizing how they may work together to promote wound healing. By tackling the problems of infection and encouraging quicker, more effective healing results, such sophisticated systems hold great potential for the treatment of contemporary wounds.